Gene: ZBTB22
Official Full Name: zinc finger and BTB domain containing 22provided by HGNC
Gene Summary: Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in chromatin. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO33370 | ZBTB22 Knockout cell line (HeLa) | Human | ZBTB22 | 1:3~1:6 | Negative | Online Inquiry |
KO33371 | ZBTB22 Knockout cell line (HCT 116) | Human | ZBTB22 | 1:2~1:4 | Negative | Online Inquiry |
KO33372 | ZBTB22 Knockout cell line (HEK293) | Human | ZBTB22 | 1:3~1:6 | Negative | Online Inquiry |
KO33373 | ZBTB22 Knockout cell line (A549) | Human | ZBTB22 | 1:3~1:4 | Negative | Online Inquiry |
ZBTB22 Gene Knockout Cell Lines represent a pivotal advancement in genetic research, specifically designed to investigate the biological roles of the ZBTB22 gene. This engineered tool consists of cell lines where the ZBTB22 gene has been specifically knocked out, enabling researchers to elucidate its function through loss-of-function studies. The knockout mechanism primarily employs CRISPR/Cas9 technology, allowing for precise gene editing that results in a complete absence of ZBTB22 protein expression.
The key functions of ZBTB22 suggest its involvement in various cellular processes, including immune response modulation and potential implications in oncogenesis. By utilizing these knockout cell lines, researchers can examine how the absence of ZBTB22 affects cell proliferation, differentiation, and interaction with other signaling pathways. This makes the ZBTB22 knockout model highly valuable for studies in molecular biology, pharmacology, and drug development.
In both research and clinical settings, the implications of ZBTB22 are significant, as aberrant regulation of this gene may contribute to autoimmune disorders and cancer. These cell lines provide a streamlined model for assessing therapeutic interventions, biomarkers, and gene regulatory networks in conditions related to ZBTB22 dysregulation.
What distinguishes the ZBTB22 Gene Knockout Cell Lines from alternative models is their rigorously validated performance and reproducibility, along with easy integration into existing experimental frameworks. Unlike traditional approaches, our product allows for rapid and efficient studies, saving resources while expediting the discovery process.
For researchers and clinicians aiming to deepen their understanding of ZBTB22’s biological contributions, these knockout cell lines are an indispensable asset. Our company prides itself on delivering high-quality biological products, backed by extensive research and development expertise, ensuring that our offerings not only meet but exceed the expectations of the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.